Physician profile
Samantha Shawn Marsh
NPI 1053743286
$639,066.09
in general payments reported to CMS, 2019-2025
10 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66K · 2022: $79K · 2023: $226K · 2024: $163K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $290K · Consulting Fee: $74K · Travel and Lodging: $74K · Honoraria: $39K · Food and Beverage: $16K · Education: $78.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $289,622.75 |
| Consulting Fee | $74,468.00 |
| Travel and Lodging | $74,416.40 |
| Honoraria | $39,491.50 |
| Food and Beverage | $15,667.87 |
| Education | $78.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450,592.09 | 2021-2025 | |
| Axsome Therapeutics, INC. | $124,630.53 | 2023-2025 | Auvelity |
| Corium, LLC | $36,674.91 | 2022-2024 | Azstarys, Azstarys |
| Otsuka America Pharmaceutical, INC. | $20,296.86 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $4,951.40 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $826.34 | 2021-2022 | |
| Allergan, INC. | $825.00 | 2021 | |
| Lundbeck LLC | $124.84 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $118.44 | 2023 | Spravato |
| Alfasigma USA, INC. | $25.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Shawn Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.